Corvus Q1 net loss $5.7M; soquelitinib PTCL ORR 39%; $30.6M financing

Corvus Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.12

Net loss $5.7M in Q1 2024 vs $7.9M in Q1 2023; R&D expense $4.1M.
Cash $22.1M at March 31, 2024; plus $30.6M from May 6 financing; projected cash into Q4 2025.
Soquelitinib Phase 1/1b PTCL: 39% ORR (5 CRs, 4 PRs) in 23 evaluable patients; disease control 61%.
Phase 3 registrational trial for soquelitinib in PTCL planned to start Q3 2024.
Ciforadenant Phase 1b/2 in RCC met predefined efficacy threshold; enrollment continues.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.